In order to bring you the best possible user experience, this site uses Javascript. If you are seeing this message, it is likely that the Javascript option in your browser is disabled. For optimal viewing of this site, please ensure that Javascript is enabled for your browser.

This content is currently on FREE ACCESS, enjoy another 18 days of free consultation

In these unprecedented times, the ESC is doing everything it can to support its community: FREE access to all ESC 365 content until 31 July: explore more than 125,000 educational resources.

From 1 August onwards, support our mission by becoming a member.

Improved diastolic function in non-diabetic patients with metabolic syndrome treated with metformin: 1 year results from MET-DIME randomized clinical trial

Session Poster session 6

Speaker Ricardo Ladeiras-Lopes

Event : EuroEcho 2018

  • Topic : imaging
  • Sub-topic : Echocardiography: Systolic and Diastolic Function
  • Session type : Poster Session

Authors : R Ladeiras-Lopes (Vila Nova de Gaia,PT), F Sampaio (Vila Nova de Gaia,PT), S Leite (Porto,PT), N Bettencourt (Porto,PT), A Leite-Moreira (Porto,PT), V Gama (Vila Nova de Gaia,PT), P Braga (Vila Nova de Gaia,PT), R Fontes-Carvalho (Vila Nova de Gaia,PT)

R Ladeiras-Lopes1 , F Sampaio1 , S Leite2 , N Bettencourt2 , A Leite-Moreira2 , V Gama1 , P Braga1 , R Fontes-Carvalho1 , 1Gaia Hospital Centre, Department of Cardiology - Vila Nova de Gaia - Portugal , 2Faculty of Medicine, University of Porto - Porto - Portugal ,

European Heart Journal - Cardiovascular Imaging ( 2019 ) 20 ( Supplement 1 ), i1220

Background: Metabolic syndrome (MetS) is highly prevalent and has a complex pathophysiology with insulin resistance as a key player. Furthermore, MetS is associated with preclinical diastolic dysfunction that impairs functional capacity and quality of life (QoL).

Purpose: This randomized trial was designed to evaluate if the addition of metformin to the standard treatment of non-diabetic patients with MetS improves diastolic dysfunction, functional capacity and QoL.

Methods: In this randomized, open-label, blinded-endpoint trial, 54 non-diabetic adults (40 to 65 years old) with MetS and diastolic dysfunction (mean e’<10.2 cm/s if 40-59 years old; mean e’<7.2 cm/s if 60-65 years old), were recruited. Patients were randomized to lifestyle counseling or lifestyle counseling plus metformin (target dose 1000 mg bid). Primary endpoint was improvement in mean e’ velocity (assessed at baseline, 6 and 12 months). Secondary endpoints were improvements in insulin resistance (HOMA-IR), functional capacity (peak oxygen uptake during cardiopulmonary exercise test), quality of life (using the SF-36 questionnaire). Linear mixed effects modelling was used for longitudinal data analysis.

Results: Fifty patients were included in this analysis (mean age=51.8±6.3; 54% males). Evaluating MetS criteria at baseline, all patients had elevated waist circumference (mean=105.1±9.6 cm), 92% were hypertensive, 58% had low HDL-cholesterol, 56% showed abnormal glucose homeostasis (median HOMA-IR=3.7, IQR 2.6-5.1) and 50% had elevated triglycerides. Metformin treatment was associated with a significant decrease in HOMA-IR at 1 year. Between-group change in the mean e’ velocity during the first year of follow-up was not significantly different in the intention-to-treat analysis (-0.34 cm/s in the control group vs +0.26 cm/s in the metformin group; p=0.132) but the difference was significant in the as-treated analysis (-0.52 cm/s in the control group vs +0.46 cm/s in the metformin group; p=0.009), adjusting for age, gender, baseline grade of diastolic dysfunction, treatment with modifiers of the renin-angiotensin-aldosterone axis and presence of symptoms of heart failure. During the 1-year follow-up there was no significant change in peak oxygen uptake (+0.1 mL/kg/min in the control group vs +0.8 mL/kg/min in the metformin group; p=0.401). In addition, there was a non-significant increase in mental component score of SF-36 (+4.83 points in the control group vs +2.17 points in the metformin group; p=0.173) and a significant increase in the physical component score of SF-36 (+3.75 points in the control group vs +4.75 points in the metformin group; p=0.023) that was not affected by treatment group.

Conclusion: In this pragmatic randomized trial, metformin treatment was associated with improved diastolic function in non-diabetic patients with MetS and diastolic dysfunction.

Based on your interests

Members get more

Join now
  • 1ESC Professional Members – access all resources from general ESC events 
  • 2ESC Association Members (Ivory, Silver, Gold) – access your Association’s resources
  • 3Under 40 or in training - with a Combined Membership, access all resources
Join now

Our sponsors

ESC 365 is supported by Bayer, Boehringer Ingelheim and Lilly Alliance, Bristol-Myers Squibb and Pfizer Alliance, Novartis Pharma AG and Vifor Pharma in the form of educational grants. The sponsors were not involved in the development of this platform and had no influence on its content.

logo esc

Our mission: To reduce the burden of cardiovascular disease

Who we are